Rchr
J-GLOBAL ID：202201020910504209
Update date: Aug. 25, 2024
Kanzaki Hiroaki
カンザキ ヒロアキ | Kanzaki Hiroaki
Affiliation and department：
Job title：
Clinical Assistant Professor
Research theme for competitive and other funds (2)：
- 2023 - 2026 肝細胞癌における抗腫瘍免疫活性の高い腫瘍微小環境を導く遺伝子異常の解明
- 2020 - 2023 FGF19・FGFR4シグナル阻害による肝癌分子標的薬の新規治療戦略
Papers (61)：
-
Tomomi Ozaki, Sae Yumita, Sadahisa Ogasawara, Makoto Fujiya, Takahiro Tsuchiya, Ryohei Yoshino, Midori Sawada, Teppei Akatsuka, Ryo Izai, Chihiro Miwa, et al. Cytokine release syndrome following durvalumab and tremelimumab in advanced hepatocellular carcinoma: A case report with cytokine and damage-associated molecular pattern analysis. Hepatology research : the official journal of the Japan Society of Hepatology. 2024
-
Kisako Fujiwara, Takayuki Kondo, Kentaro Fujimoto, Sae Yumita, Keita Ogawa, Takamasa Ishino, Miyuki Nakagawa, Terunao Iwanaga, Satoshi Tsuchiya, Keisuke Koroki, et al. Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma. Journal of gastroenterology. 2024. 59. 6. 515-525
-
Masanori Inoue, Sadahisa Ogasawara, Kazufumi Kobayashi, Tomomi Okubo, Norio Itokawa, Masamichi Obu, Kentaro Fujimoto, Hidemi Unozawa, Sae Yumita, Kisako Fujiwara, et al. Assessment of Macrovascular Invasion in Advanced Hepatocellular Carcinoma: Clinical Implications and Treatment Outcomes with Systemic Therapy. Liver Cancer. 2024
-
Kazufumi Kobayashi, Sadahisa Ogasawara, Susumu Maruta, Tomomi Okubo, Norio Itokawa, Yuki Haga, Yuya Seko, Michihisa Moriguchi, Shunji Watanabe, Yuki Shiko, et al. A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma and high tumor burden: The LAUNCH study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023
-
Takayuki Kondo, Kentaro Fujimoto, Kisako Fujiwara, Sae Yumita, Takamasa Ishino, Keita Ogawa, Miyuki Nakagawa, Terunao Iwanaga, Keisuke Koroki, Hiroaki Kanzaki, et al. Potential of circulating receptor-interacting protein kinase 3 levels as a marker of acute liver injury. Scientific reports. 2023. 13. 1. 14043-14043
ｍore...
MISC (135)：
-
神崎洋彰, 小笠原定久, 加藤直也. 肝細胞癌の進化と腫瘍微小環境の変遷. 日本消化器病学会雑誌(Web). 2024. 121
-
米本卓弥, 小笠原定久, 對田尚, 赤塚鉄平, 伊在井亮, 片山慶一, 三輪千尋, 藤本健太郎, 小暮禎祥, 小川慶太, et al. 進行肝細胞癌に対するデュルバルマブ/トレメリムマブ併用療法によりirAE腸炎を発症した症例の検討. 肝臓. 2023. 64. Supplement 3
-
高橋知也, 叶川直哉, 弓田冴, 小川慶太, 石野貴雅, 岩永光巨, 藤原希彩子, 中川美由貴, 神崎洋彰, 興梠慧輔, et al. A case of severe alcoholic hepatitis resolved through the use of a clinical ethics consultation team. アルコールと医学生物学. 2023. 42
-
興梠慧輔, 小笠原定久, 神崎洋彰, 小林和史, 中村昌人, 叶川直哉, 近藤孝行, 鈴木英一郎, 大岡美彦, 中本晋吾, et al. RESORCE基準外の肝細胞癌に対するregorafenibの有用性を検証するランダム化比較試験. 日本癌治療学会学術集会(Web). 2023. 61st
-
小林和史, 小笠原定久, 丸田享, 大久保知美, 森口理久, 神崎洋彰, 興梠慧輔, 叶川直哉, 仕子優樹, 稲葉洋介, et al. 肝内腫瘍量50%以上,門脈本幹・胆管浸潤症例を含むChild-Pugh AおよびBの進行肝細胞癌に対するレンバチニブの安全性と有効性の探索:LAUNCH試験. 日本肝がん分子標的治療研究会プログラム・抄録集. 2023. 28th
ｍore...
Patents (1)：
Awards (1)：
- 2021/11 - Japan Digestive Disease Week Young Scientist Award
Return to Previous Page
